<DOC>
	<DOCNO>NCT00053287</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Thalidomide may stop growth cancer cell stop blood flow tumor . Combining chemotherapy thalidomide may kill cancer cell . PURPOSE : Phase II trial study effectiveness combine fludarabine , carboplatin , topotecan thalidomide treat patient relapsed refractory acute myeloid leukemia , chronic myelogenous leukemia , advance myelodysplastic syndrome .</brief_summary>
	<brief_title>Fludarabine/Carboplatin/Topotecan w/Thalidomide Relapsed/Refractory AML , CML MDS</brief_title>
	<detailed_description>OBJECTIVES : - Determine response rate patient relapsed/refractory high-risk acute myeloid leukemia , chronic myelogenous leukemia , advance myelodysplastic syndrome treat fludarabine , carboplatin , topotecan , thalidomide . - Determine non-hematologic toxicity profile time hematopoietic recovery patient treat regimen . - Determine effect regimen change biologic parameter may predict response patient . - Correlate bone marrow microvascular density treatment response patient . - Determine prognostic value pretreatment plasma serum level vascular endothelial growth factor ( VEGF ) and/or modulation serum level VEGF treatment predict response patient . OUTLINE : Patients stratify accord diagnosis ( previously untreated acute leukemia v ) . Patients receive fludarabine IV 5-10 minute carboplatin IV 24 hour day 1-5 followed topotecan IV continuously 72 hour . Patients receive oral thalidomide daily begin within day 1-3 continue absence disease progression unacceptable toxicity . Patients residual disease day 16-18 may receive second course chemotherapy . Patients achieve remission may receive third course chemotherapy consolidation begin 4-8 week completion prior chemotherapy . Patients follow monthly 6 month . PROJECTED ACCRUAL : A total 40 patient ( 20 per stratum ) accrue study .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis 1 following : Acute myeloid leukemia meeting 1 follow criterion : Previously untreated candidate anthracyclinebased chemotherapy In first second relapse refractory Secondary chemotherapy antecedent hematologic disorder treat 1 prior intensive induction regimen Chronic myelogenous leukemia blast crisis diagnosis prior imatinib mesylate Myelodysplastic syndrome ( MDS ) Refractory anemia excess blast ( RAEB ) RAEB transformation Must meet least 1 follow criterion : Absolute neutrophil count great 500/mm^3 Platelet red cell transfusiondependent 1 prior intensive induction chemotherapy Acute promyelocytic leukemia ( 15 , 17 ) Failed prior treatment tretinoin arsenic Relapsed disease least 3 month prior autologous stem cell transplantation No active CNS leukemia PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 03 Life expectancy At least 8 week Hematopoietic See Disease Characteristics Hepatic Bilirubin great 2.0 mg/dL AST ALT less 3 time upper limit normal Renal Creatinine clearance least 50 mL/min Cardiovascular Ejection fraction least 40 % No poorly control cardiac disease Pulmonary No poorly control pulmonary disease Other Not pregnant nursing Negative pregnancy test Fertile female patient must use 1 highly effective 1 additional method contraception 4 week , , least 4 week study Male patient must use effective contraception 4 week study Willing able comply System Thalidomide Education Prescribing Safety ( STEPS ) program HIV negative No poorly control infection No active malignancy No severe peripheral neuropathy PRIOR CONCURRENT THERAPY : Biologic therapy See Disease Characteristics Prior thalidomide allow MDS At least 5 day since prior hematopoietic growth factor At least 2 week since prior biologic therapy No prior allogeneic bone marrow transplantation Chemotherapy See Disease Characteristics At least 24 hour since prior hydroxyurea Endocrine therapy At least 24 hour since prior corticosteroid Radiotherapy Not specify Surgery Not specify Other At least 2 week since prior cytotoxic anticancer therapy Prior amifostine allow MDS</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>adult acute promyelocytic leukemia ( M3 )</keyword>
	<keyword>refractory anemia excess blast transformation</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>untreated adult acute myeloid leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>atypical chronic myeloid leukemia</keyword>
	<keyword>myelodysplastic/myeloproliferative disease , unclassifiable</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
</DOC>